Henry Lowman

Henry Lowman, PhD, has more than 30 years of experience in the biotechnology industry with expertise in research and development of biotherapeutics. He earned a BA in chemistry at the Johns Hopkins University and a PhD in chemistry at Purdue University before being named an NIH postdoctoral fellow at Genentech, then moved on to roles as scientist and senior scientist, before leading Genentech’s antibody engineering department, with research and early-development team-leader roles in several therapeutic antibody programs, including VEGF, IgE, and CD20 antibodies. Dr. Lowman led R&D teams at CytomX Therapeutics as vice president of research and later chief scientific officer (2010-2014) in work on the Probody™ platform, and at Triphase Accelerator as executive director/VP (2015-2018). In 2013 he was named one of the top 25 most influential individuals in the antibody field by Total Biopharma. His career interests include structure-based drug design, structure-function analysis and molecular diversity techniques. Dr. Lowman is an author on more than 70 scientific publications, an inventor on more than 80 issued U.S. patents, and an editorial board member for the antibody journal mAbs. He is currently an advisor/board member for several organizations.